Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rabeprazole ER vs Ranitidine for Maintenance of Healed Erosive GERD
NCT00838526Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2008
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rabeprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Percentage of Participants With Maintenance of Complete Healing of eGERD at 26 weeks. Started Aug 2008; status: completed.
02
Drugs
rabeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00838526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00838526.